Upregulation of centromere protein F is linked to aggressive prostate cancers

References

• TorreLABrayFSiegelRLFerlayJLortet-TieulentJJemalAGlobal cancer statistics, 2012CA Cancer J Clin20156528710825651787
   PubMed Web of Science ®Google Scholar
• WiltTJBrawerMKJonesKMProstate Cancer Intervention versus Observation Trial (PIVOT) Study GroupRadical prostatectomy versus observation for localized prostate cancerN Engl J Med2012367320321322808955
   PubMed Web of Science ®Google Scholar
• ThompsonIMJrTangenCMProstate cancer: uncertainty and a way forwardN Engl J Med2012367327027122808963
   PubMed Web of Science ®Google Scholar
• ZhaoMa LZhuXXMitosin/CENP-F in mitosis, transcriptional control, and differentiationJ Biomed Sci200613220521316456711
   PubMed Web of Science ®Google Scholar
• LiaoHWinkfeinRJMackGRattnerJBYenTJCENP-F is a protein of the nuclear matrix that assembles onto kinetochores at late G2 and is rapidly degraded after mitosisJ Cell Biol199513035075187542657
   PubMed Web of Science ®Google Scholar
• ZhuXManciniMAChangKHCharacterization of a novel 350-kilodalton nuclear phosphoprotein that is specifically involved in mitotic-phase progressionMol Cell Biol1995159501750297651420
   PubMed Web of Science ®Google Scholar
• JohnsonVLScottMIHoltSVHusseinDTaylorSSBub1 is required for kinetochore localization of BubR1, Cenp-E, Cenp-F and Mad2, and chromosome congressionJ Cell Sci2004117(Pt 81577158915020684
   PubMed Web of Science ®Google Scholar
• PooleyRDMoynihanKLSoukoulisVMurine CENPF interacts with syntaxin 4 in the regulation of vesicular transportJ Cell Sci2008121Pt 203413342118827011
   PubMed Web of Science ®Google Scholar
• PooleyRDReddySSoukoulisVRolandJTGoldenringJRBaderDMCytLEK1 is a regulator of plasma membrane recycling through its interaction with SNAP-25Mol Biol Cell20061773176318616672379
   PubMed Web of Science ®Google Scholar
• AytesAMitrofanovaALefebvreCCross-species regulatory network analysis identifies a synergistic interaction between FOXM1 and CENPF that drives prostate cancer malignancyCancer Cell201425563865124823640
   PubMed Web of Science ®Google Scholar
• O’BrienSLFaganAFoxEJCENP-F expression is associated with poor prognosis and chromosomal instability in patients with primary breast cancerInt J Cancer200712071434144317205517
   PubMed Web of Science ®Google Scholar
• CaoJYLiuLChenSPPrognostic significance and therapeutic implications of centromere protein F expression in human nasopharyngeal carcinomaMol Cancer2010923720828406
   PubMed Web of Science ®Google Scholar
• DaiYLiuLZengTCharacterization of the oncogenic function of centromere protein F in hepatocellular carcinomaBiochem Biophys Res Commun2013436471171823791740
   PubMed Web of Science ®Google Scholar
• MiYJGaoJXieJDPrognostic relevance and therapeutic implications of centromere protein F expression in patients with esophageal squamous cell carcinomaDis Esophagus201326663664323163484
   PubMed Web of Science ®Google Scholar
• KoonNSchneider-StockRSarlomo-RikalaMMolecular targets for tumour progression in gastrointestinal stromal tumoursGut200453223524014724156
   PubMed Web of Science ®Google Scholar
• ErlansonMCasianoCATanEMLindhJRoosGLandbergGImmunohistochemical analysis of the proliferation associated nuclear antigen CENP-F in non-Hodgkin’s lymphomaMod Pathol199912169749950165
   PubMed Web of Science ®Google Scholar
• ZhuoYJXiMWanYPEnhanced expression of centromere protein F predicts clinical progression and prognosis in patients with prostate cancerInt J Mol Med201535496697225647485
   PubMed Web of Science ®Google Scholar
• SchlommTIwersLKirsteinPClinical significance of p53 alterations in surgically treated prostate cancersMod Pathol200821111371137818552821
   PubMed Web of Science ®Google Scholar
• SauterGSteurerSClauditzTSClinical utility of quantitative Gleason grading in prostate biopsies and prostatectomy specimensEur Urol201669459259826542947
   PubMed Web of Science ®Google Scholar
• KononenJBubendorfLKallioniemiATissue microarrays for high-throughput molecular profiling of tumor specimensNat Med1998478448479662379
   PubMed Web of Science ®Google Scholar
• WeischenfeldtJSimonRFeuerbachLIntegrative genomic analyses reveal an androgen-driven somatic alteration landscape in early-onset prostate cancerCancer Cell201323215917023410972
   PubMed Web of Science ®Google Scholar
• MinnerSEnodienMSirmaHERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of anti-hormonal therapyClin Cancer Res201117185878588821791629
   PubMed Web of Science ®Google Scholar
• BurkhardtLFuchsSKrohnACHD1 is a 5q21 tumor suppressor required for ERG rearrangement in prostate cancerCancer Res20137392795280523492366
   PubMed Web of Science ®Google Scholar
• KluthMHesseJHeinlAGenomic deletion of MAP3K7 at 6q12-22 is associated with early PSA recurrence in prostate cancer and absence of TMPRSS2:ERG fusionsMod Pathol201326797598323370768
   PubMed Web of Science ®Google Scholar
• KrohnADiedlerTBurkhardtLGenomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancerAm J Pathol2012181240141222705054
   PubMed Web of Science ®Google Scholar
• KrohnASeidelABurkhardtLRecurrent deletion of 3p13 targets multiple tumour suppressor genes and defines a distinct subgroup of aggressive ERG fusion-positive prostate cancersJ Pathol2013231113014123794398
   PubMed Web of Science ®Google Scholar
• TennstedtPKösterPBrüchmannAThe impact of the number of cores on tissue microarray studies investigating prostate cancer biomarkersInt J Oncol201240126126821956230
   PubMed Web of Science ®Google Scholar
• LaoukiliJKooistraMRBrásAFoxM1 is required for execution of the mitotic programme and chromosome stabilityNat Cell Biol20057212613615654331
   PubMed Web of Science ®Google Scholar
• TomlinsSARhodesDRPernerSRecurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancerScience2005310574864464816254181
   PubMed Web of Science ®Google Scholar
• BraseJCJohannesMMannspergerHTMPRSS2-ERG -specific transcriptional modulation is associated with prostate cancer biomarkers and TGF-β signalingBMC Cancer20111150722142399
   PubMed Web of Science ®Google Scholar
• DreosRAmbrosiniGPérierRCBucherPThe eukaryotic promoter database: expansion of EPDnew and new promoter analysis toolsNucleic Acids Res201543Database issueD92D9625378343
   PubMedGoogle Scholar
• TaylorBSSchultzNHieronymusHIntegrative genomic profiling of human prostate cancerCancer Cell2010181112220579941
   PubMed Web of Science ®Google Scholar
• LinSCKaoCYLeeHJDysregulation of miRNAs-COUP-TFII-FOXM1-CENPF axis contributes to the metastasis of prostate cancerNat Commun201671141827108958
   PubMed Web of Science ®Google Scholar
• Vlaeminck-GuillemVVanackerJMVergerAMutual repression of transcriptional activation between the ETS-related factor ERG and estrogen receptorOncogene200322508072808414603248
   PubMed Web of Science ®Google Scholar
• GruppKJedrzejewskaKTsourlakisMCHigh mitochondria content is associated with prostate cancer disease progressionMol Cancer201312114524261794
   PubMedGoogle Scholar
• GruppKOspina-KlinckDTsourlakisMCNY-ESO-1 expression is tightly linked to TMPRSS2-ERG fusion in prostate cancerProstate201474101012102224789172
   PubMed Web of Science ®Google Scholar
• StummLBurkhardtLSteurerSStrong expression of the neuronal transcription factor FOXP2 is linked to an increased risk of early PSA recurrence in ERG fusion-negative cancersJ Clin Pathol201366756356823559350
   PubMed Web of Science ®Google Scholar
• BurdelskiCBujupiETsourlakisMCLoss of SOX9 expression is associated with PSA recurrence in ERG-positive and PTEN deleted prostate cancersPLoS One2015106e012852526030748
   PubMed Web of Science ®Google Scholar
• BurdelskiCMenanDTsourlakisMCThe prognostic value of SUMO1/Sentrin specific peptidase 1 (SENP1) in prostate cancer is limited to ERG-fusion positive tumors lacking PTEN deletionBMC Cancer20151553826202067
   PubMed Web of Science ®Google Scholar
• GruppKBoumesliRTsourlakisMCThe prognostic impact of high Nijmegen breakage syndrome (NBS1) gene expression in ERG-negative prostate cancers lacking PTEN deletion is driven by KPNA2 expressionInt J Cancer201413561399140724510842
   PubMed Web of Science ®Google Scholar
• SunJLiuWAdamsTSDNA copy number alterations in prostate cancers: a combined analysis of published CGH studiesProstate200767769270017342750
   PubMed Web of Science ®Google Scholar
• WangYHeXNgeowJEngCGATA2 negatively regulates PTEN by preventing nuclear translocation of androgen receptor and by androgen-independent suppression of PTEN transcription in breast cancerHum Mol Genet201221356957622021428
   PubMed Web of Science ®Google Scholar
• SauterGClauditzTSteurerSIntegrating tertiary Gleason 5 patterns into quantitative Gleason grading in prostate biopsies and prostatectomy specimensEur Urol201873567468328117112
   PubMed Web of Science ®Google Scholar
• BrownHKOttewellPDColemanREHolenIThe kinetochore protein Cenp-F is a potential novel target for zoledronic acid in breast cancer cellsJ Cell Mol Med201115350151320015195
   PubMed Web of Science ®Google Scholar
• LebokPÖzdenCSchlommTUpregulation of centromer protein F (CENPF) is linked to an aggressive subset of ERG-negative prostate cancersPathologe2017385482
   Google Scholar